Clinical Trial Update: LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 LOC-R01 study evaluates lenalidomide and ibrutinib in combination with Rituximab-Methotrexate-Procarbazine-Vincristine (R-MPV) for diffuse large B-cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma
• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Lenalidomide (lenalidomide)
• METHOTREXATE (METHOTREXATE)
• Procarbazine (procarbazine)
• Rituximab (rituximab)
• Vincristine (vincristine)

Snippet

Sponsor: Institut Curie | Conditions: Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Primary | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING